PT-112 showed safety profile in heavily pre-treated patients, improving pharmacokinetic and pharmacodynamic features, such as: prominent osteotropism, monotherapy efficacy in pulmonary/prostate cancers and thymoma, combinatorial efficacy in PD-L1 blockage in CRPC, and activity in immunocompetent mouse models of breast and colorectal cancer linked to the initiation of ICD. Here, CD274 is linked to prostate cancer.